|The registration for this conference has ended.||RegistrationCenter|
Register Today! On-Demand Teleconference - KyprolisTM - New Myeloma Treatment KyprolisTM, the latest breakthrough therapy for myeloma, is a proteasome inhibitor (like Velcade®), that was FDA-approved last week for advanced myeloma. The MMRF is proud to have played an integral role in the development of this exciting new treatment.
A. Keith Stewart, MBChB, Mayo Clinic in Arizona, KyprolisTM Investigator to provide a clinical overview and perspective.
Laura McBride, RN, Hackensack University, KyprolisTM Research Nurse to discuss treatment management and perspective.
Anne Quinn Young, MPH, Mulitple Myeloma Research Foundation
Please use the following form to register for this on-demand teleconference. You will receive an email confirmation shortly after you complete the registration. Don't forget to add beaconlive.com to your whitelist!
If you are unable to register online or did not receive your confirmation email (don't forget to check your Bulk email folder), please contact our Registration Desk at 866-872-5840 (international callers please dial 972-588-8036). You can also contact us by email